Abstract
BackgroundTCZ is an IL-6-receptor signalling inhibitor licensed for use in RA. Because TCZ may impact how IL-6 affects T-cell activation and B-cell differentiation, response of TCZ-treated pts to vaccination is...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
